About us

A daring vision

There are times when a discovery is made and its importance is astounding.

The discovery of biomolecular condensates is such a breakthrough. A revelation so profound, it completely transforms the understanding of cellular function and organization.

We have advanced this new foundational principle of cell biology to shape a daring vision – that the dysregulation of biomolecular condensates explains the root cause of complex diseases and paves the way to novel therapies.

We apply cutting-edge in-silico tools to accelerate how we explore and codify the relationship between condensate biology and human disease, igniting therapeutic possibilities in ways previously unimagined.

We have assembled the most extraordinary talent in condensate science, drug discovery and data science, collaborating across continents and disciplines, and emerging as the world’s leading condensate biotechnology company on a brave path to develop a new generation of medicines.

We are Dewpoint Therapeutics

Pioneering scientific founders

Anthony Hyman, PhD
Richard Young, PhD
American Association
of Arts & Sciences
Phillip Sharp, PhD
Nobel Laureate

Dewpoint, the origin of our name

One evening in the late fall of 2018, Tony Hyman was at his home in Dresden, talking by speakerphone with his new startup co-founder Rick Young back in Cambridge. “Rick and I were discussing how to name the company,” Hyman remembers. “I was walking around the room, and we were coming up with one terrible name after another. ‘Phase Space’ was something I was keen on, and Rick was like, ‘That’s terrible, Tony.’ And then Suzanne came out of the kitchen and said, ‘Why don’t you call it Dewpoint?’”

Hyman and his wife Suzanne Eaton met in California when Hyman was a postdoc, then continued together to Heidelberg, where they both conducted research in cell biology, ultimately moving to Dresden to start the Max Plank Institute of Molecular Cell Biology and Genetics.

In addition to being a leading scientific voice at MPI, Eaton was a Renaissance woman—an accomplished writer, chef, concert pianist, mother, and martial-arts practitioner who was also beloved by the MPI-CBG staff as a thoughtful and infinitely attentive listener and advisor. “She was the best of America in that way,” Hyman says. “She had a real mastery of language and words, a precision – and coming up with our name ‘Dewpoint’ represented that ability to think about language properly.”

With a touch of imagination, our name evokes the moment of phase separation inside cells, when intrinsically disordered proteins and other biomolecules form condensates.

A new biology

Our founders and advisors explain how condensates drive cell function and solve biological mysteries.
The emerging science of biomolecular condensates completely transforms the understanding of cellular function and organization, solving some of biology’s greatest mysteries.

Our Team

We have assembled the most extraordinary talent in condensate science, drug discovery and data science, collaborating across continents and disciplines, emerging as the world’s leading condensate biotechnology company on a brave path to develop a new generation of medicine.

What makes Dewpoint unique?

Select tab to view content :

Our story so far

1903

Santiago Ramón y Cajal documents membrane-free cellular structures, now known to be condensates

June 2009

Dewpoint co-founder Tony Hyman and colleagues publish pivotal paper revealing the potential of condensates

August 2018

Dewpoint founded by pioneering scientists Tony Hyman, Rick Young and Amir Nashat with Nobel Laureate Phil Sharp appointed as SAB chair

October 2018

US Operations begin

January 2019

Series A funding, $60M raised

March 2019

German operations begin

November 2019

$100M deal with Bayer propels our research in cardiovascular diseases

July 2020

$350M deal with Merck kicks off research into treatments for HIV

September 2020

Series B funding, $77M raised

January 2021

$239 deal with Pfizer starts development of treatments for a rare form of muscular dystrophy

February 2022

Series C funding, $150M raised

May 2022

Foundational platform technology patent granted by US Patent Office

August 2022

“Modulating biomolecular condensates: a novel approach to drug discovery” published in Nature Reviews Drug Discovery

September 2022

Dewpoint co-founder Tony Hyman awarded 2023 Breakthrough Prize in Life Sciences

November 2022

Dewpoint opens Frankfurt office

November 2022

Dewpoint Therapeutics granted second breakthrough condensates platform technology patent by US Patent Office

March 2023

$55M deal with Novo Nordisk opens collaboration in insulin resistance and diabetic complications with financing potential up to $690 million

September 2023

Partnership with Chemify to develop a suite of digitally discovered and automatically synthesized novel molecules against condensate targets

November 2023

Strategic collaboration with Evotec to advance Dewpoint’s oncology programs to “IND” status

Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
USA
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science